Work

Forecasting Cytokine Storms with New Predictive Biomarkers

Year: 2016

Type: article

Abstract: T cells genetically modified with CD19 chimeric antigen receptors have produced impressive clinical responses in patients with refractory B-cell malignancies, but therapeutic responses are often accompanied by cytokine release syndrome (CRS), which can cause significant morbidity and mortality. Teachey and colleagues have identified predictive biomarkers for this complication that may allow testing of earlier intervention with agents such as the IL6 receptor blocker tocilizumab to evaluate whether CRS can be ameliorated without jeopardizing clinical responses. Cancer Discov; 6(6); 579-80. ©2016 AACR.See related article by Teachey et al., p. 664.

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-16-0493

Authors: Rayne H. Rouce, Helen E. Heslop

Institutions: Houston Methodist, Baylor College of Medicine, Texas Children's Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Heart, Lung, and Blood Institute, National Cancer Institute